Clinical Trial Update: Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating Ciltacabtagene Autoleucel for high-risk smoldering multiple myeloma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Smoldering Multiple Myeloma

Drugs mentioned

• Ciltacabtagene autoleucel (cilta-cel)

Snippet

Sponsor: PETHEMA Foundation | Conditions: High Risk Smoldering Multiple Myeloma | Phase 2 | Status: RECRUITING